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Key Points
• Immunological dysregu-
lation may underlie un-
usual autoimmune
diseases, which also
deserve to be investi-
gated from a genetic
point of view.
Introduction
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder characterized by
microvascular platelet clumping and microangiopathic hemolytic anemia, often accompanied by
renal dysfunction and neurological symptoms.1 The underlying pathophysiological mechanism is
due to a defective ADAMTS13 protein, either congenital or secondary to the anti-ADAMTS
antibodies that switch off its function. Acquired TTP occurs mainly in women, rarely in children, and
has also been described in association with known autoimmune disorders (ie, systemic lupus
erythematosus).1,2
The gold standard therapy for TTP is plasma exchange together with high-dose steroids or
immunoglobulins. Drugs such as rituximab are indicated in cases of failure/relapse. Vincristine,
cyclophosphamide, azathioprine, and cyclosporine have also been used with a certain efficacy,3-5
and splenectomy has been performed with a positive outcome in patients with refractory or relapsing
disease.6 To the best of our knowledge, correlation between acquired TTP and immune dysregulation
due to a defect in components of the apoptosis pathway have never previously been described.
Case description
An Ecuador-born female patient came to us for the first time for observation at 18 years of age due to
easy bruising and hematuria. Her platelet count was 43 109/L, and acute non-autoimmune hemolytic
anemia was indicated (hemoglobin, 6 g/dL; lactate dehydrogenase, 2964 IU/L; reticulocyte count,
2003 109/L; haptoglobin,,2 mg/dL; schistocytes on the blood smear; and negative results on direct
and indirect antiglobulin tests). The patient carried antithyroglobulin antibodies; in addition, antinuclear
antibodies, antibodies against double-stranded DNA, extractable nuclear antigens, antiphospholipid
antibodies, and complement components (C3 and C4) were negative. Previously in Ecuador, the patient
had had 2 similar episodes at the age of 10 and 15 years, successfully treated with transfusions and
immunoglobulins. A long remission occurred between the 2 events without any therapy.
The differential diagnosis initially considered between relapsing Evans syndrome treated with high-dose
steroids and immunoglobulins and atypical hemolytic uremic syndrome/TTP. The patient was empirically
treated with plasma infusions, with substantial improvement in clinical status.
Following steroid suspension, the patient’s platelet count dropped again below 10 3 109/L, and
hemolysis relapsed. This oriented treatment toward a plasma exchange procedure. Unfortunately, the
patient could not tolerate the procedure because of a severe reaction characterized by malaise,
hypotension, and hives. Rescue therapy with a second cycle with immunoglobulin was administered,
and mycophenolate mofetil (MMF) at a dose of 600 mg/mq twice a day was started as “maintenance”
treatment.
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The choice of MMF was based on our recent encouraging results in
refractory cytopenias.7 Given the stability of the hematological
values, after 2 weeks of MMF, the therapeutic strategy was not
shifted to rituximab. We preferred MMF to rituximab, even after
confirmation of the TTP diagnosis, because the good initial
response reported in autoimmune cytopenias is outbalanced by
rarely maintained long-term remission and by the risk of iatrogenic,
deep and prolonged hypogammaglobulinemia.8,9 Indeed, rituximab
therapy, mainly in the pre–“low-dose” era, had a stronger impact
on B cells and immunoglobulin G concentrations, which remain
below the threshold for many months (requiring, in some cases,
immunoglobulin replacement therapy).10
Methods and results
Despite normal platelet values and resolution of hemolysis, low
levels of ADAMTS13 (,3% activity as measured by using the
FRETS-VWF73 assay; normal range, 45%-138%) and positivity
for antibodies against ADAMTS13 (62 U/mL as measured by
using the Technozym ADAMTS-13 Inhibitor assay [Technoclone
GmbH]) were shown.11 The patient continued MMF, and remission
lasted .12 months. After that time span, another relapse occurred
that was attributed to poor MMF compliance. A new plasma
exchange cycle (plus steroids) was performed, and this time it
was well tolerated. After 2 months, stable remission was again
achieved; the patient has been motivated to adequately comply
with the MMF regimen. To date, 19 months later, the patient is
again in remission (steroid free), and the trough MMF plasma
levels are in the therapeutic range (1-4 mg/mL).12
ADAMTS13 activity remained below the threshold, and antibodies
against ADAMTS13 persisted as positive both in the “active”
periods and during the remission phases of the disease. An
expanded immunological evaluation was normal (even the CD31
T-cell receptor ab1 CD4– CD8– double-negative T cells), lympho-
proliferation was absent, and the in vitro FAS-mediated apoptosis
test result was normal. Molecular studies were performed by using
an enlarged next-generation sequencing panel, which surprisingly
showed a homozygous variant in CASP8 and a heterozygous
variant in CASP10. The caspase-8 gene showed a homozygous
mutation, c.2T.C (RefSeq NM_001080125.1), which led to
a p.Met1Thr change, affecting the start codon. This variant,
although rare in different populations, is relatively common in
South America, with an allelic frequency of 12% and with ;1%
to 2% of the population being homozygote-CC (ExAC Browser,
http://exac.broadinstitute.org/).
In fact, western blotting of the extract of lymphoblast cells obtained
from the patient showed normal expression of procaspase-8
(Figure 1A), probably a “different” protein with uncertain function-
ality. (Informed consent had been obtained from the patient, and all
experiments were performed in accordance with the approved
guidelines.) Treatment with FAS-L aimed to induce apoptosis
generated a cleavage activation of caspase-8 only in the wild-type
cell line and not in the patient’s lymphoblasts, suggesting that the
mutation altered protein function and maintained an impaired apopto-
sis pathway. The heterozygous CASP10 variant (NM_032977.3:
c.1564T.A) leading to a Leu522Ile missense change did not
substantially alter the expression of the protein (Figure 1A-B). This
variant is generally classified as a high-frequency polymorphism
(EXAC DATABASE, http://exac.broadinstitute.org/) even if it was
reported with a probably damaging role in most prediction tools; it has
also been shown to be associated with an impaired apoptotic
capacity.13,14
The additional weak cleavage inactivation of the PARP protein,
along with FAS-L treatment that did not induce any apoptotic death
(Figure 1A), suggests an overall reduction in apoptotic activity in the
patient’s lymphoid cells.
The same experimental setting adopted for FAS-L was repeated
with TRAIL, the other apoptosis inducer, thus confirming the
impairment of the CASP pathway in the patient’s lymphoid cells
(Figure 1B).15
Discussion
The current report contains 2 main peculiarities: the association
between acquired TTP and mutations in the CASP8/10 genes,
usually responsible for different disorders, and its management
with a “nonconventional” immunosuppressive drug. Caspases
are cysteine proteases that play a central role in apoptosis.
Caspase-8 and caspase-10 may be the first enzymes in the
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Figure 1. Lower cell death after stimulation of
apoptosis by FAS-L/TRAIL and reduction of
CASP8 and PARP cleavage due to reduced
activity of CASP10 protein in our patient (pt)
compared to the control. (A) Apoptosis proteins
cleavage and cell death induced by FAS-L (10 ng/
mL); values given as percentage. (B) Apoptosis
proteins cleavage and cell death stimulated by
TRAIL (100 mM); values given as percentage. cl,
cleaved; wt, wild type.
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proteolytic cascade that are activated by FAS ligand and tumor
necrosis factor. The absence of an immunomodulatory function of
CASP8, enhanced by its lack of negative regulation by CASP10,
interrupts the cleavage of CASP3, increases PARP pathway
signaling, and causes hyperactivation of Akt–mammalian target of
rapamycin.16,17 According to the literature, mutations in either
CASP8 or CASP10 (being implicated in programming life and
death of immune cells) influence immune surveillance of malignan-
cies and cause lymphoproliferation (autoimmune lymphoproliferative
syndrome type IIA and B).13,18-21 In addition, the interplay between
caspase-8 and caspase-10 proteins, which share substrates and
functions, is crucial for the maintenance of regular apoptosis.21 The
hypothesis, recently addressed in an article from our group, is that the
association of 2 variants on genes involved in the same pathway, even
if polymorphic, might contribute to the development of immune
dysregulation.14 Indeed, we speculate that the mutations found
in our patient do not affect lymphocyte accumulation but
generate a negative synergy expressed as autoimmunity against
the ADAMTS13 protein. Even if direct causality between the
hyperactivation of Akt–mammalian target of rapamycin and
autoimmune TTP cannot be proved, an immune dysregulation
was at the basis of the phenomenon affecting the patient. It
is worth noting that our patient was also studied for 315
adjunctive genes involved in hematological disorders, immune
deficiencies, and immune dysregulations, with negative results.
Nevertheless, we cannot exclude that other genetic lesions in
genes not covered by our panel might have contributed to
the clinical phenotype of the study patient, but the knowledge of
the impaired apoptosis pathway represents a suggestion for
a tailored treatment.
Regarding the response to treatment, MMF, on account of the
inhibition of B, T, and natural killer cells, has been shown to be
effective in autoimmune cytopenia and in a number of other
autoimmune diseases.22-24 In this patient, MMF seemed to have
had a certain efficacy in the maintenance of autoimmunity suppression
against ADAMTS13 with no undesirable effects. Moreover, according
to a recent article, persistent low ADAMTS13 activity, as
observed in our patient, seems to be a predictor of relapse
and thus indicates a possible role for a preemptive immuno-
suppression regimen.25
The very last “lesson” of this experience is that patients presenting
with refractory autoimmune cytopenia and/or unusual autoimmune
targets should be studied by using an extended genetic panel
directed to identify “disimmunity.” The aim is to better understand
the mechanism and identify possible targeted drugs.
Acknowledgment
This work was supported by the Italian Ministry of Health (Ricerca
corrente 2019).
Authorship
Contribution: F.F., C.D., and M.M. conceived and designed the re-
search and wrote the paper; E.C., A.G., I.C., R.V., I.M., F.P., and F.C.
performed the laboratory investigations; A.M. andA.B. collected data
and drafted the paper; and E.P., C.M., M.C., and F.P. collected the
materials and cared for the patient.
Conflict-of-interest disclosure: I.M. has received honoraria for
participating as a speaker at an educational meeting organized by
Instrumentation Laboratory and for participating at a Sanofi advisory
board meeting. F.P. is a member of the scientific advisory board of
Bioverativ, Roche, Sanofi, and Takeda. The remaining authors de-
clare no competing financial interests.
ORCID profiles: F.F., 0000-0003-1504-5511; E.C., 0000-
0001-5910-9260; A.B., 0000-0002-1712-6529; E.P., 0000-0003-
2812-653X; A.G., 0000-0002-4570-3485; I.C., 0000-0001-8732-
1955; R.V., 0000-0002-2522-3716; C.M., 0000-0002-7371-
1431; M.C., 0000-0002-5925-4318; F. Pierri, 0000-0002-0005-
4127; I.M., 0000-0002-5059-5212; F. Peyvandi, 0000-0001-
7423-9864; F.C., 0000-0003-0016-3400; C.D., 0000-0002-
5980-5474; M.M., 0000-0002-9816-1704.
Correspondence: F. Fioredda, Unit of Haematology, IRCCS
Istituto Giannina Gaslini, Largo G Gaslini 5, 16147 Genoa, Italy;
e-mail: francescafioredda@gaslini.org.
References
1. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836-2846.
2. Joly BS, Stepanian A, Leblanc T, et al; French Reference Center for Thrombotic Microangiopathies. Child-onset and adolescent-onset acquired
thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
Lancet Haematol. 2016;3(11):e537-e546.
3. Rock GA, Shumak KH, Buskard NA, et al; Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of
thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6):393-397.
4. Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015;
125(10):1526-1531.
5. Scully M, Goodship T, How I. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164(6):
759-766.
6. Kappers-Klunne MC, Wijermans P, Fijnheer R, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2005;
130(5):768-776.
7. Miano M, How I. How I manage Evans syndrome and AIHA cases in children. Br J Haematol. 2016;172(4):524-534.
8. Svahn J, Fioredda F, Calvillo M, et al. Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants. Br J Haematol. 2009;145(1):
96-100.
3434 FIOREDDA et al 12 NOVEMBER 2019 x VOLUME 3, NUMBER 21
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/3/21/3432/1506182/advancesadv2019000575.pdf by U
N
IVER
SITA D
EG
LI STU
D
I D
I M
ILAN
O
 user on 23 July 2020
9. Patel VL, Mahe´vas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood.
2012;119(25):5989-5995.
10. Sacco KA, Abraham RS. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy. 2018;
10(8):713-728.
11. Lotta LA, Valsecchi C, Pontiggia S, et al. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic
thrombocytopenic purpura. J Thromb Haemost. 2014;12(3):329-336.
12. Gellermann J, Weber L, Pape L, To¨nshoff B, Hoyer P, Querfeld U; Gesellschaft fu¨r Pa¨diatrische Nephrologie (GPN). Mycophenolate mofetil versus
cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol. 2013;24(10):1689-1697.
13. Hu Z, Li C, Chen K, et al. Single nucleotide polymorphisms in selected apoptotic genes and BPDE-induced apoptotic capacity in apparently normal
primary lymphocytes: a genotype-phenotype correlation analysis. J Cancer Epidemiol. 2008;2008:147905.
14. Miano M, Cappelli E, Pezzulla A, et al. FAS-mediated apoptosis impairment in patients with ALPS/ALPS-like phenotype carrying variants on CASP10
gene [published online ahead of print July 15, 2019]. Br J Hematol. doi: 10.1111/bjh.16098.
15. Sedger LM, Katewa A, Pettersen AK, et al. Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL
double-deficient mice. Blood. 2010;115(16):3258-3268.
16. Horn S, Hughes MA, Schilling R, et al. Caspase-10 negatively regulates caspase-8-mediated cell death, switching the response to CD95L in favor of
NF-kB activation and cell survival. Cell Reports. 2017;19(4):785-797.
17. Tapodi A, Debreceni B, Hanto K, et al. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1
inhibition in oxidative stress. J Biol Chem. 2005;280(42):35767-35775.
18. Vo¨lkl S, Rensing-Ehl A, Allga¨uer A, et al. Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune
lymphoproliferative syndrome. Blood. 2016;128(2):227-238.
19. Zhu S, Hsu AP, Vacek MM, et al. Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome. Hum
Genet. 2006;119(3):284-294.
20. Chun HJ, Zheng L, AhmadM, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency.Nature.
2002;419(6905):395-399.
21. Fischer U, Stroh C, Schulze-Osthoff K. Unique and overlapping substrate specificities of caspase-8 and caspase-10. Oncogene. 2006;25(1):152-159.
22. Miano M, Scalzone M, Perri K, et al. Mycophenolate mofetil and sirolimus as second or further line treatment in children with chronic refractory primitive or
secondary autoimmune cytopenias: a single centre experience. Br J Haematol. 2015;171(2):247-253.
23. Davis LS, Reimold AM. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatology. 2017;56:
i100-i113.
24. Cropley A, Weltman M. The use of immunosuppression in autoimmune hepatitis: a current literature review. Clin Mol Hepatol. 2017;23(1):22-26.
25. Mazepa MA, Masias C, Chaturvedi S. How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns. Blood.
2019;134(5):415-420.
12 NOVEMBER 2019 x VOLUME 3, NUMBER 21 TTP AND APOPTOTIC DEFECT: CONNECTION AND TREATMENT 3435
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/3/21/3432/1506182/advancesadv2019000575.pdf by U
N
IVER
SITA D
EG
LI STU
D
I D
I M
ILAN
O
 user on 23 July 2020
